日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Use of Creative Frameworks in Health Care to Solve Data and Information Problems: Scoping Review

在医疗保健领域运用创新框架解决数据和信息问题:范围界定综述

Mess, Elisabeth Veronica; Kramer, Frank; Krumme, Julia; Kanelakis, Nico; Teynor, Alexandra

Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2

超越传统的基于结构的药物设计:铁络合、应变和水在缺氧诱导因子脯氨酰羟化酶2抑制剂结合中的作用

Bembenek, Scott D; Venkatesan, Hariharan; Peltier, Hillary M; Rosen, Mark D; Barrett, Terrance D; Kanelakis, Kimon C; Palomino, Heather L; Brondstetter, Theresa I; Mirzadegan, Taraneh; Rabinowitz, Michael H

Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats

脯氨酰羟化酶抑制剂可纠正大鼠的功能性铁缺乏症和炎症引起的贫血

Barrett, Terrance D; Palomino, Heather L; Brondstetter, Theresa I; Kanelakis, Kimon C; Wu, Xiaodong; Yan, Wen; Merton, Katherine P; Schoetens, Freddy; Ma, Jing Ying; Skaptason, Judy; Gao, Jingjin; Tran, Da-Thao; Venkatesan, Hariharan; Rosen, Mark D; Shankley, Nigel P; Rabinowitz, Michael H

Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor

1-(5-氯-6-(三氟甲氧基)-1H-苯并咪唑-2-基)-1H-吡唑-4-羧酸(JNJ-42041935)的药理学表征,一种有效的选择性缺氧诱导因子脯氨酰羟化酶抑制剂

Terrance D Barrett, Heather L Palomino, Theresa I Brondstetter, Kimon C Kanelakis, Xiaodong Wu, Peter V Haug, Wen Yan, Andrew Young, Hong Hua, Juliet C Hart, Da-Thao Tran, Hariharan Venkatesan, Mark D Rosen, Hillary M Peltier, Kia Sepassi, Michele C Rizzolio, Scott D Bembenek, Tara Mirzadegan, Micha

Functional Characterization of the Canine Heme-Regulated eIF2alpha Kinase: Regulation of Protein Synthesis

犬血红素调控的eIF2α激酶的功能表征:蛋白质合成的调控

Kanelakis, Kimon C; Pyati, Jayashree; Wagaman, Pamela C; Chuang, Jui Chang; Yang, Young; Shankley, Nigel P